Vitrolife AB (publ) VITR
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold if you own; consider adding only after further Q2 confirmation that Consumables/Technologies momentum persists and Genetics actions track to plan. Reduce only if your risk budget cannot tolerate ongoing FX/legal/execution risk.
Stabilized margins and the buyback program provide support, but weak organic growth and execution risk in Genetics justify the continued hold signal.
Sentiment has strengthened slightly after the earnings beat and analyst updates, although uncertainty around organic growth and China remains.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 23 Oct 2026 — Report showed higher revenue and organic growth than expected, driven by strong Technologies growth offsetting weakness in China.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Vitrolife AB (publ) is a medtech company supplying consumables, equipment and services to IVF clinics globally. The group includes genetic services via Igenomix and technologies such as EmbryoScope. FY2025 results were heavily impacted by large impairments and restructuring in Genetic Services.
Bull case
The buyback program and proven margin uplift from restructuring can support earnings per share even if growth remains muted.
Bear case
Weak organic growth and high execution risk in Genetics, together with currency and regulatory risks in the US, may continue to weigh on re-rating.
Why this signal
Stabilized margins and the buyback program provide support, but weak organic growth and execution risk in Genetics justify the continued hold signal.
Recent news
Vitrolife released its Q3 report on 22 October with revenue of 884 MSEK and 6 percent organic growth, beating expectations. The share rose about 5 percent on the day to 102.70 SEK. Strong performance in Technologies (+21 percent organic) partly offset weakness in China.